270 related articles for article (PubMed ID: 24096568)
1. The molecular diversity of Luminal A breast tumors.
Ciriello G; Sinha R; Hoadley KA; Jacobsen AS; Reva B; Perou CM; Sander C; Schultz N
Breast Cancer Res Treat; 2013 Oct; 141(3):409-20. PubMed ID: 24096568
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network
Nature; 2012 Oct; 490(7418):61-70. PubMed ID: 23000897
[TBL] [Abstract][Full Text] [Related]
3. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.
Boyault S; Drouet Y; Navarro C; Bachelot T; Lasset C; Treilleux I; Tabone E; Puisieux A; Wang Q
Breast Cancer Res Treat; 2012 Feb; 132(1):29-39. PubMed ID: 21512767
[TBL] [Abstract][Full Text] [Related]
4. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
5. GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival.
Jiang YZ; Yu KD; Zuo WJ; Peng WT; Shao ZM
Cancer; 2014 May; 120(9):1329-37. PubMed ID: 24477928
[TBL] [Abstract][Full Text] [Related]
6. DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.
Conway K; Edmiston SN; May R; Kuan PF; Chu H; Bryant C; Tse CK; Swift-Scanlan T; Geradts J; Troester MA; Millikan RC
Breast Cancer Res; 2014 Oct; 16(5):450. PubMed ID: 25287138
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA-AKT pathway mutations in micropapillary breast carcinoma.
Flatley E; Ang D; Warrick A; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2013 Jul; 44(7):1320-7. PubMed ID: 23352210
[TBL] [Abstract][Full Text] [Related]
8. Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups.
van den Broek AJ; Broeks A; Horlings HM; Canisius SV; Braaf LM; Langerød A; Van't Veer LJ; Schmidt MK
Breast Cancer Res Treat; 2011 Nov; 130(2):599-608. PubMed ID: 21667122
[TBL] [Abstract][Full Text] [Related]
9. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.
López-Knowles E; O'Toole SA; McNeil CM; Millar EK; Qiu MR; Crea P; Daly RJ; Musgrove EA; Sutherland RL
Int J Cancer; 2010 Mar; 126(5):1121-31. PubMed ID: 19685490
[TBL] [Abstract][Full Text] [Related]
10. Polarity gene alterations in pure invasive micropapillary carcinomas of the breast.
Gruel N; Benhamo V; Bhalshankar J; Popova T; Fréneaux P; Arnould L; Mariani O; Stern MH; Raynal V; Sastre-Garau X; Rouzier R; Delattre O; Vincent-Salomon A
Breast Cancer Res; 2014 May; 16(3):R46. PubMed ID: 24887297
[TBL] [Abstract][Full Text] [Related]
11. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
[TBL] [Abstract][Full Text] [Related]
12. Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors.
Lopez G; Costanza J; Colleoni M; Fontana L; Ferrero S; Miozzo M; Fusco N
Int J Mol Sci; 2019 Jan; 20(3):. PubMed ID: 30691046
[TBL] [Abstract][Full Text] [Related]
13. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
Rudolph M; Anzeneder T; Schulz A; Beckmann G; Byrne AT; Jeffers M; Pena C; Politz O; Köchert K; Vonk R; Reischl J
BMC Cancer; 2016 Aug; 16():622. PubMed ID: 27515171
[TBL] [Abstract][Full Text] [Related]
14. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases.
Michelucci A; Di Cristofano C; Lami A; Collecchi P; Caligo A; Decarli N; Leopizzi M; Aretini P; Bertacca G; Porta RP; Ricci S; Della Rocca C; Stanta G; Bevilacqua G; Cavazzana A
Diagn Mol Pathol; 2009 Dec; 18(4):200-5. PubMed ID: 19861897
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Hennessy BT; Gonzalez-Angulo AM; Stemke-Hale K; Gilcrease MZ; Krishnamurthy S; Lee JS; Fridlyand J; Sahin A; Agarwal R; Joy C; Liu W; Stivers D; Baggerly K; Carey M; Lluch A; Monteagudo C; He X; Weigman V; Fan C; Palazzo J; Hortobagyi GN; Nolden LK; Wang NJ; Valero V; Gray JW; Perou CM; Mills GB
Cancer Res; 2009 May; 69(10):4116-24. PubMed ID: 19435916
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological Characteristics of
Lee MH; Cho JH; Kwon SY; Jung SJ; Lee JH
Int J Med Sci; 2020; 17(8):1131-1135. PubMed ID: 32410843
[TBL] [Abstract][Full Text] [Related]
18. Mucinous breast carcinomas lack PIK3CA and AKT1 mutations.
Kehr EL; Jorns JM; Ang D; Warrick A; Neff T; Degnin M; Lewis R; Beadling C; Corless CL; Troxell ML
Hum Pathol; 2012 Dec; 43(12):2207-12. PubMed ID: 22705004
[TBL] [Abstract][Full Text] [Related]
19. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer.
Stella S; Vitale SR; Massimino M; Motta G; Longhitano C; Lanzafame K; Martorana F; Fazzari C; Vecchio GM; Tirrò E; Inzerilli N; Carciotto R; Manzella L; Caruso M; Vigneri P
Cancer Genomics Proteomics; 2022; 19(4):464-476. PubMed ID: 35732329
[TBL] [Abstract][Full Text] [Related]
20. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]